Thomas Gad | Founder, Interim CEO & President |
Sue Smith | SVP & Chief Commercial Officer |
Bo Kruse | EVP, Secretary, Treasurer & CFO |
Vignesh Rajah | Chief Medical Officer |
Alec Stranahan | Bank of America |
Etzer Darout | BMO Capital Markets |
William Maughan | Canaccord Genuity |
Taylor Hanley | JPMorgan |
Edouard Mullarky | Guggenheim Securities |
Good morning, and welcome to the Y-mAbs Therapeutics, Inc.'s Earnings Call for the Fourth Quarter 2022. [Operator Instructions] As a reminder, today's conference will be recorded.
Let me quickly remind you that the following discussion contains certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model and development; commercialization and product distribution plans; current and future clinical and preclinical studies, and our research and development programs; expectations related to the timing of the initiation and completion of regulatory submissions; regulatory, marketing and reimbursement approvals, including statements with respect to future development of other development programs, potential for DANYELZA territory expansion and advancement of SADA; collaborations or strategic partnerships and the potential benefits thereof; expectations related to our anticipated cash runway and the sufficiency of our cash resources; DANYELZA revenue guidance and other guidance for 2023; and our financial performance, including our estimates regarding revenues, expenses and capital expenditure requirements; and other statements that are not historical facts.
Because forward-looking statements involve risks and uncertainties, they are not guarantees of future performance, and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 30, 2023.